Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
EXPRESS plans to test exaluren against placebo over 52 weeks, with topline results expected in 1H 2029.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eloxx Pharmaceuticals (ELOX) received FDA clearance to begin U.S. clinical testing of exaluren for nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD). The clearance allows U.S. sites to join EXPRESS, its global Phase 2 trial. The study plans to enroll approximately 60 adults with genetically confirmed PKD1 or PKD2 nonsense mutations, randomized 1:1 to exaluren or placebo for 52 weeks. Its primary endpoint is annualized change in height-adjusted total kidney volume (htTKV), measured by MRI.
Eloxx is activating sites in the United States and other countries, with first patient dosing planned in 3Q 2027 and topline 52-week results expected in 1H 2029. FDA feedback identified a potential basis for Breakthrough Therapy Designation, and htTKV is a potential surrogate endpoint for accelerated approval. Any expedited pathway or designation depends on clinical results and further FDA discussions.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA IND clearance enables U.S. clinical sites to join the global Phase 2 EXPRESS trial.
- Minor point. Forward-looking: it has not happened yet and may not happen.EXPRESS plans approximately 60 adults, randomized 1:1 to exaluren or placebo for 52 weeks.
- Minor point. Forward-looking: it has not happened yet and may not happen.Site activation is underway; first dosing is planned in 3Q 2027, with topline results expected in 1H 2029.
- Minor point. Forward-looking: it has not happened yet and may not happen.FDA feedback identifies a potential basis for Breakthrough Therapy Designation; htTKV is a potential accelerated-approval endpoint.
- Minor pointOrphan drug designation is held for ADPKD in the United States and Europe.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Expedited pathways or designations depend on clinical results and further FDA discussions.
Key Figures
- Planned enrollment
- Approximately 60 adults
- EXPRESS Phase 2 study
- Randomization
- 1:1
- Exaluren or placebo
- Treatment period
- 52 weeks
- EXPRESS Phase 2 study
- First patient dosing
- 3Q 2027
- Expected trial milestone
- Topline results
- 1H 2029
- Expected 52-week results
Previous Clinical trial Reports
-
The earlier announcement finalized the EXPRESS protocol; this clearance enables U.S. clinical-site initiation.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
investigational new drug (ind) application regulatory
breakthrough therapy designation regulatory
surrogate endpoint regulatory
orphan drug designation regulatory
adpkd medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- FDA clearance of the IND enables Eloxx to open
U.S . clinical sites for EXPRESS, its global Phase 2 study of exaluren in nonsense-mutation ADPKD - EXPRESS will randomize approximately 60 patients 1:1 to exaluren or placebo for 52 weeks, with annualized htTKV growth as the primary endpoint; first patient dosing expected in 3Q 2027 and topline data in 1H 2029
- FDA pre-IND feedback indicated that a substantial and durable htTKV effect could support Breakthrough Therapy Designation; FDA also lists htTKV as a potential surrogate endpoint for accelerated approval in ADPKD
EXPRESS Phase 2 Study
EXPRESS is designed to enroll approximately 60 adults with genetically confirmed PKD1 or PKD2 nonsense mutations, randomized 1:1 to exaluren or placebo for 52 weeks. The primary endpoint is the annualized rate of change in height-adjusted total kidney volume (htTKV), assessed by MRI at baseline and Weeks 28, 36 and 52. Eloxx is now activating sites in
Regulatory Pathway
In written pre-IND feedback, FDA noted that a substantial and durable htTKV treatment effect, with supporting eGFR and safety data, could serve as a potential basis for Breakthrough Therapy Designation. FDA also identifies change in htTKV as a potential surrogate endpoint for accelerated approval in ADPKD. Exaluren holds orphan drug designation for ADPKD in
"IND clearance is an important milestone for people living with nonsense-mutation ADPKD, who have no therapy that addresses the genetic cause of their disease," said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. "With the trial design finalized, our focus now is execution: activating sites and preparing to dose the first patient in the third quarter of 2027."
About Nonsense Mutation ADPKD
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease, affecting an estimated 160,000 to 200,000 people in
About Exaluren
Exaluren is Eloxx's investigational, small-molecule ribosomal modulator designed to promote readthrough of premature stop codons caused by nonsense mutations, enabling production of full-length, functional protein. Exaluren is being developed for rare kidney diseases caused by nonsense mutations, including nonsense mutation Alport syndrome and nonsense mutation autosomal dominant polycystic kidney disease (ADPKD). The FDA and the European Commission have each granted orphan drug designations to exaluren for the treatment of Alport syndrome and ADPKD.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Eloxx's lead product candidate, exaluren, is being developed for the treatment of rare kidney diseases, including nonsense mutation Alport syndrome and nonsense mutation autosomal dominant polycystic kidney disease (ADPKD). Eloxx has also exclusively licensed its product candidate, ZKN-013, to Almirall, S.A., which is developing it for the treatment of rare dermatological diseases associated with nonsense mutations.
For more information, please visit www.eloxxpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation statements regarding the expected timing of the initiation of, and results from, clinical trials of the Company's product candidates, including the Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome and the EXPRESS Phase 2 clinical trial of exaluren in nonsense mutation ADPKD; the FDA's clearance of the Company's IND for exaluren and the anticipated initiation of the EXPRESS trial in the United States; the design of the EXPRESS trial and the potential for exaluren to receive Breakthrough Therapy designation or pursue accelerated approval; the potential benefits of orphan drug designation; the Company's collaboration with Almirall and the potential to receive milestone and royalty payments; and the potential of the Company's product candidates to treat nonsense mutations, are forward-looking statements. Forward-looking statements can be identified by words such as "aim," "may," "will," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "potential," "seeks," or "continue," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and are subject to known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied due to various important factors, including, but not limited to, the Company's need for and ability to obtain additional capital; the uncertainty and expense of clinical development; the fact that results from preclinical studies and early clinical trials are not necessarily predictive of future results; and other important factors discussed under the caption "Risk Factors" and elsewhere in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 and its other filings with the SEC, accessible on the SEC's website at www.sec.gov and on the "Financials & Filings" page of the Company's website. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements contained herein.
Contact
Investor Relations
Eloxx Pharmaceuticals, Inc.
ir@eloxxpharma.com
(781) 577-5300
View original content to download multimedia:https://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-announces-fda-clearance-of-investigational-new-drug-application-for-exaluren-in-nonsense-mutation-adpkd-302922973.html
SOURCE Eloxx Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does FDA clearance mean for Eloxx's exaluren ADPKD trial?
The IND clearance enables Eloxx to initiate EXPRESS at U.S. clinical sites. EXPRESS is a global Phase 2 study in adults with genetically confirmed PKD1 or PKD2 nonsense mutations, comparing exaluren with placebo over 52 weeks.
When does Eloxx expect exaluren EXPRESS dosing and results?
Eloxx plans first patient dosing in 3Q 2027 and expects topline 52-week results in 1H 2029. Site activation is underway in the United States and other countries.
What evidence could support Breakthrough Therapy Designation for Eloxx's exaluren?
FDA's written pre-IND feedback identified a substantial and durable htTKV treatment effect, supported by estimated kidney filtration rate (eGFR) and safety data, as a potential basis for Breakthrough Therapy Designation. Any expedited pathway or designation would depend on clinical results and further FDA discussions.
How will Eloxx measure the primary endpoint in EXPRESS?
EXPRESS will assess height-adjusted total kidney volume by MRI at baseline and Weeks 28, 36 and 52. The primary endpoint is the annualized rate of change in that measure.